2,2'-{ethane-1,2-diylbis[imino(2-oxoethane-2,1-diyl)oxybenzene-3,1-diylcarbonylimino(2-methylindolizine-1,3-diyl)carbonyl(2,4-dioxo-1,4-dihydroquinazoline-7,3(2H)-diyl)]}diacetic acid | 1446266-21-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,2'-{ethane-1,2-diylbis[imino(2-oxoethane-2,1-diyl)oxybenzene-3,1-diylcarbonylimino(2-methylindolizine-1,3-diyl)carbonyl(2,4-dioxo-1,4-dihydroquinazoline-7,3(2H)-diyl)]}diacetic acid
• 英文别名: 2-[7-[1-[[3-[2-[2-[[2-[3-[[3-[3-(carboxymethyl)-2,4-dioxo-1H-quinazoline-7-carbonyl]-2-methylindolizin-1-yl]carbamoyl]phenoxy]acetyl]amino]ethylamino]-2-oxoethoxy]benzoyl]amino]-2-methylindolizine-3-carbonyl]-2,4-dioxo-1H-quinazolin-3-yl]acetic acid
• CAS: 1446266-21-2
• 化学式: C₆₀H₄₈N₁₀O₁₆
• 分子量: 1165.1
• InChiKey: RNSNHWUXDRJTFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  86
• 可旋转键数：
  21
• 环数：
  10.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  351
• 氢给体数：
  8
• 氢受体数：
  16

文献信息

• [EN] FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF<br/>[FR] COMPOSÉS DIMÈRES AGONISTES DU RÉCEPTEUR FGF (FGFR), LEUR PROCÉDÉ DE PRÉPARATION ET LEUR USAGE THÉRAPEUTIQUE
  申请人：SANOFI SA

  公开号：WO2013098763A1

  公开（公告）日：2013-07-04

  The invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce FGFR dimerization, having the general formula: M -L-M 2 in which M and M 2, which may be identical or different, each represent, independently of one another, a monomer unit Mand L represents a linker group which links M1 and M2 covalently with the monomer unit which follows (Formula M). Process for the preparation thereof and therapeutic use thereof.

  这项发明涉及一种新型杂环化合物，它们是诱导FGFR二聚化的吡唑吡啶衍生物，具有一般式：M-L-M2，其中M和M2，可以相同也可以不同，分别表示单体单元M和L代表将M1和M2以共价键与其后的单体单元连接的连接基团（式M）。其制备方法和治疗用途。
• FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof
  申请人：Sanofi

  公开号：US20140378483A1

  公开（公告）日：2014-12-25

  The invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce FGFR dimerization, having the general formula: M-L-M2 in which M and M2, which may be identical or different, each represent, independently of one another, a monomer unit M and L represents a linker group which links M 1 and M 2 covalently with the monomer unit which follows (Formula M). Process for the preparation thereof and therapeutic use thereof.

  本发明涉及一种新型杂环化合物，为诱导FGFR二聚化的吡唑吡啶衍生物，其通式为：M-L-M2，其中M和M2，可以相同也可以不同，分别独立地表示单体单元M，L表示连接M1和M2的连接基，该连接基通过共价键连接后续单体单元（M公式）。其制备方法和治疗用途。
• FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：SANOFI

  公开号：EP2797930A1

  公开（公告）日：2014-11-05
• US9206177B2
  申请人：——

  公开号：US9206177B2

  公开（公告）日：2015-12-08